Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

NovoCure Limited - Ordinary Shares (NQ:NVCR)

14.72 +0.59 (+4.18%)
Streaming Delayed Price Updated: 4:00 PM EDT, Jun 24, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 1,549,306
Open 14.17
Bid (Size) 12.77 (100)
Ask (Size) 15.23 (200)
Prev. Close 14.13
Today's Range 14.17 - 15.11
52wk Range 9.820 - 18.92
Shares Outstanding 103,647,871
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
News headline image
HeartFlow vs. NovoCure: Which Emerging Healthcare Stock Is a Better Buy in 2026? ↗
AI-powered diagnostics meet global oncology innovation as two medical disruptors post strong revenue growth, yet face distinct risk and valuation profiles. 
Via The Motley Fool
Topics Artificial Intelligence
News headline image
NovoCure vs. Omeros: Which Emerging Pharmaceutical Stock Is a Better Buy in 2026? ↗
Both companies target serious health challenges, but their financials and risk profiles reveal sharply different paths for growth-focused investors. 
Via The Motley Fool

Performance

YTD
+12.2%
+12.2%
1 Month
-19.4%
-19.4%
3 Month
+29.6%
+29.6%
6 Month
+10.9%
+10.9%
1 Year
-11.4%
-11.4%

More News

Read More
News headline image
NVCR Investors Have Opportunity to Join NovoCure Limited Fraud Investigation with the Schall Law Firm
From The Schall Law Firm
Via Business Wire
Novocure (NASDAQ: NVCR) Q1 Revenue Beat and Path to Profitability Drive 9% Share Jump ↗
Via Chartmill
Novocure Ltd (NASDAQ:NVCR) Reports Mixed Q4 2025 Results, Stock Falls on Revenue Miss ↗
Via Chartmill
News headline image
Amgen vs. NovoCure: Which Health Care Stock Is a Better Buy in 2026? ↗
Via The Motley Fool
Thursday's session: gap up and gap down stocks ↗
Via Chartmill
These stocks that are showing activity before the opening bell on Thursday. ↗
Via Chartmill
News headline image
Novocure Announces Topline Data from the Phase 3 TRIDENT Trial Evaluating Earlier Use of Tumor Treating Fields Therapy in Newly Diagnosed Glioblastoma
From Novocure
Via Business Wire
News headline image
CEO Sells 34K Shares of Biotech Stock, Valued at $615,000, According to Latest SEC Filing ↗
Via The Motley Fool
Topics Regulatory Compliance
News headline image
Vericel Revenue Jumped 20%. One Biotech Investor Just Reported Adding $63 Million More ↗
Via The Motley Fool
Topics Regulatory Compliance
News headline image
3 Overlooked Stocks Set to Soar in 2026 ↗
Via The Motley Fool
News headline image
NovoCure (NVCR) Q1 2026 Earnings Transcript ↗
Via The Motley Fool
Topics Supply Chain
Thursday's session: gap up and gap down stocks ↗
Via Chartmill
News headline image
Novocure Reports First Quarter 2026 Financial Results
From Novocure
Via Business Wire
News headline image
Novocure to Report First Quarter 2026 Financial Results
From Novocure
Via Business Wire
News headline image
Novocure Announces Positive Topline Results from Phase 2 PANOVA-4 Clinical Trial of Tumor Treating Fields (TTFields) Therapy for Metastatic Pancreatic Cancer
From Novocure
Via Business Wire
News headline image
Novocure Announces Optune Lua® Receives Reimbursement Approval in Japan for the Treatment of Non-Small Cell Lung Cancer
From Novocure
Via Business Wire
News headline image
Novocure to Participate in 2026 Leerink Global Healthcare Conference
From Novocure
Via Business Wire
News headline image
NovoCure (NVCR) Q4 2025 Earnings Call Transcript ↗
Via The Motley Fool
Topics Earnings World Trade
News headline image
Novocure Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Company Update
From Novocure
Via Business Wire
The market is filled with gapping stocks in Wednesday's session. ↗
Via Chartmill
News headline image
Tumor Treating Fields (TTFields) Therapy to be Covered for Patients with Newly Diagnosed Glioblastoma Through British Columbia Cancer (BC Cancer)
From Novocure
Via Business Wire
News headline image
Soleus Adds a Significant Number of Celcuity Shares ↗
Via The Motley Fool
AI: The Great Disruptor or the Great Divider? ↗
Via Chartmill

Frequently Asked Questions

Is NovoCure Limited - Ordinary Shares publicly traded?
Yes, NovoCure Limited - Ordinary Shares is publicly traded.
What exchange does NovoCure Limited - Ordinary Shares trade on?
NovoCure Limited - Ordinary Shares trades on the Nasdaq Stock Market
What is the ticker symbol for NovoCure Limited - Ordinary Shares?
The ticker symbol for NovoCure Limited - Ordinary Shares is NVCR on the Nasdaq Stock Market
What is the current price of NovoCure Limited - Ordinary Shares?
The current price of NovoCure Limited - Ordinary Shares is 14.72
When was NovoCure Limited - Ordinary Shares last traded?
The last trade of NovoCure Limited - Ordinary Shares was at 06/24/26 04:00 PM ET
What is the market capitalization of NovoCure Limited - Ordinary Shares?
The market capitalization of NovoCure Limited - Ordinary Shares is 1.53B
How many shares of NovoCure Limited - Ordinary Shares are outstanding?
NovoCure Limited - Ordinary Shares has 2B shares outstanding.
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.